Glasdegib

Last Updated: 04/28/2026

Need to find the closest trial?
Sort By Distance
Save trials for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
1 clinical trial found

    Phase 3 Study to Assess Gemtuzumab, in Combination With Standard Chemotherapy, on MRD Levels, in Adult, 18-60 Years, With Previously Untreated de Novo Fav-interm Risk AML

    Phase 3 Study to Assess Gemtuzumab, in Combination With Standard Chemotherapy, on MRD Levels, in Adult, 18-60 Years, With Previously Untreated de Novo Fav-interm Risk AML

    Who is this study for: Adult patients with Acute Myeloid Leukemia
    Enrollment Status: Recruiting
    Publish Date: November 08, 2024
    Intervention Type: Drug
    Study Drugs: Glasdegib, Gemtuzumab
    Study Phase: Phase 3

    Summary: MRD driven study. Addition of gemtuzumab to conventional chemotherapy to reduce MRD of patients with favorable/intermediate-risk AML. Post-consolidation assessment of MRD.

    Showing 1-1 of 1

    Last Updated: 04/28/2026